JP2013538206A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538206A5
JP2013538206A5 JP2013525400A JP2013525400A JP2013538206A5 JP 2013538206 A5 JP2013538206 A5 JP 2013538206A5 JP 2013525400 A JP2013525400 A JP 2013525400A JP 2013525400 A JP2013525400 A JP 2013525400A JP 2013538206 A5 JP2013538206 A5 JP 2013538206A5
Authority
JP
Japan
Prior art keywords
disorders
benzenesulfonyl
pyrrolidine
methoxy
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013525400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538206A (ja
JP5744203B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/053693 external-priority patent/WO2012025877A1/en
Publication of JP2013538206A publication Critical patent/JP2013538206A/ja
Publication of JP2013538206A5 publication Critical patent/JP2013538206A5/ja
Application granted granted Critical
Publication of JP5744203B2 publication Critical patent/JP5744203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013525400A 2010-08-24 2011-08-23 オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体 Expired - Fee Related JP5744203B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2010/053799 2010-08-24
IB2010053799 2010-08-24
PCT/IB2011/053693 WO2012025877A1 (en) 2010-08-24 2011-08-23 Proline sulfonamide derivatives as orexin receptor antagonists

Publications (3)

Publication Number Publication Date
JP2013538206A JP2013538206A (ja) 2013-10-10
JP2013538206A5 true JP2013538206A5 (enExample) 2014-10-09
JP5744203B2 JP5744203B2 (ja) 2015-07-08

Family

ID=44658790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013525400A Expired - Fee Related JP5744203B2 (ja) 2010-08-24 2011-08-23 オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体

Country Status (9)

Country Link
US (3) US8895606B2 (enExample)
EP (1) EP2608787B1 (enExample)
JP (1) JP5744203B2 (enExample)
KR (1) KR101802726B1 (enExample)
CN (1) CN103079563B (enExample)
CA (1) CA2807000C (enExample)
ES (1) ES2769607T3 (enExample)
TW (1) TW201209037A (enExample)
WO (1) WO2012025877A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2608787B1 (en) 2010-08-24 2019-11-20 Idorsia Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체
ES2651475T3 (es) 2013-12-03 2018-01-26 Idorsia Pharmaceuticals Ltd Forma cristalina de (S)-(2-(6-cloro-7-metil-1H-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2H-1,2,3-triazol-2-il)fenil)metanona y su uso como antagonistas del receptor de orexina
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
MY179605A (en) 2013-12-04 2020-11-11 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
US20230146937A1 (en) * 2020-04-09 2023-05-11 Arizona Board Of Regents On Behalf Of The University Of Arizona Kappa opiod receptor antagonists for treating pain-related sleep disorders
EP4356909A1 (en) * 2022-10-17 2024-04-24 Selabtec Sciences, SLU 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides derivatives and use thereof
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5822111B2 (ja) 1977-10-29 1983-05-06 協和醗酵工業株式会社 柑橘類果実の改質剤
JPS5581857A (en) 1978-12-15 1980-06-20 Kyowa Hakko Kogyo Co Ltd Modifier of citrus fruit
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
WO1999048492A1 (en) 1998-03-26 1999-09-30 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
DE10035144A1 (de) 2000-07-19 2002-01-31 Merck Patent Gmbh Cyclische Aminosäurederivate
GB0225938D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
EP2415760A3 (en) 2003-02-20 2012-02-22 Encysive Pharmaceuticals, Inc. CCR-9 antagonists
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
CA2550958A1 (en) 2003-12-22 2005-07-07 Astellas Pharma Inc. Ornithine derivatives as prostaglandin e2 agonists or antagonists
KR100848747B1 (ko) 2004-03-01 2008-07-25 액테리온 파마슈티칼 리미티드 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
CA2644010A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
US20100029736A1 (en) 2006-07-14 2010-02-04 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2583963A1 (en) 2008-01-08 2013-04-24 Purdue Pharma L.P. Proline analogs as ligands for cannabinoid receptors for the treatment of pain
MX2010007968A (es) * 2008-02-12 2010-08-04 Hoffmann La Roche Derivados de sulfonamida piperidina.
WO2010077836A2 (en) 2009-01-05 2010-07-08 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the cb2 receptor
ES2350548B1 (es) 2009-06-25 2011-09-29 Institut Univ. De Ciència I Tecnologia, S.A. N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
ES2351323B1 (es) 2009-06-26 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
ES2351452B1 (es) 2009-07-01 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
EP2608787B1 (en) 2010-08-24 2019-11-20 Idorsia Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체

Similar Documents

Publication Publication Date Title
JP2013538206A5 (enExample)
EP2282795A4 (en) TREATMENT OF RESPIRATORY DISEASES
IN2014DN09434A (enExample)
CN104812762A8 (en) Substituted annulated pyrimidines and triazines, and use thereof
IL205624A (en) Carboxamide, Sulfonamide and Amine Compounds, Their Pharmaceutical Preparations
JP2010529118A5 (enExample)
JP2012502885A5 (enExample)
JP2015501783A5 (enExample)
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
JP2015504870A5 (enExample)
BR112014031360A2 (pt) derivado de metil amina cíclica heteroaromática
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
GEP201606526B (en) 5-ht3 receptor antagonists
NZ604379A (en) Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k
EA032951B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
JP2015522522A5 (enExample)
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
EA201171172A1 (ru) Применение в терапии производных хиназолиндиона
IL216149A (en) Heterocyclic phenoxymethyl compounds, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of central nervous system disorders
EP2849787A4 (en) LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING ENGINE NEURONS
JP2012136529A5 (enExample)
HUE037300T2 (hu) Szerotonin 5-HT3 receptor antagonisták lezionális vesztibuláris zavarok kezelésében való felhasználásra
JP2015521642A5 (enExample)
EP2384746A3 (en) Dual release oral tablet compositions of dexlansoprazole